CClinicalTrials.gg
Status unknownNCT03458143Updated Mar 13, 2018

Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval

An observational study in Oocyte Retrieval, Sedation, Conscious and Ventilatory Depression, sponsored by Erasme University Hospital. Status unknown at 1 site in Belgium. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by Erasme University Hospital · Observational

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
Female
01

Study summary

This study evaluates the effect of the addition of ketamine to a conscious sedation protocol including remifentanil during oocyte retrieval. The investigators will have 2 groups with different target effect site concentrations, namely 150 ng/ml and 200 ng/ml.

Read the detailed description

The actual protocol for conscious sedation during oocyte retrieval in at the Erasmus hospital (Brussels) consists of Remifentanil in TCI-mode, with premedication by Midazolam. However, episodes of bradypnaea with or without desaturation are still common.

The primary objective is to observe if with the addition of ketamine, it is possible to significantly reduce the dose of Remifentanil, in order to avoid episodes of respiratory depression caused by the opioid.

The secondary outcomes measured, will be the pain levels experienced by the patient, the sedation level, and the satisfaction of the patients after the procedure.

02

Conditions studied

  • Oocyte Retrieval
  • Sedation, Conscious
  • Ventilatory Depression

Keywords

  • ketamine
  • remifentanil
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Female patients in good health, with informed consent, undergoing oocyte retrieval at the Erasmus Hospital.

Inclusion criteria

  • patients having an oocyte retrieval

Exclusion criteria

Exclusion Criteria:

  • BMI > 30
  • endometriosis
  • contraindications to ketamine
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • ketamine 150 ng/ml

    The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.

    Drug: Ketamine 150 ng/ml · Drug: Remifentanil · Procedure: Oocyte retrieval

  • ketamine 200 ng/ml

    The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.

    Drug: Remifentanil · Procedure: Oocyte retrieval · Drug: Ketamine 200 ng/ml

Interventions

  • DrugKetamine 150 ng/ml

    conscious sedation in TCI-mode

    Also known as: conscious sedation

  • DrugRemifentanil

    conscious sedation in TCI-mode

    Also known as: conscious sedation

  • ProcedureOocyte retrieval

    Oocyte retrieval for In Vitro Fertilization

  • DrugKetamine 200 ng/ml

    conscious sedation in TCI-mode

    Also known as: conscious sedation

05

What researchers measure

Primary outcomes

  1. respiratory depression

    respiratory rate (number of inspiration per minute)

    Time frame: through study completion, an average of 2 months

  2. Respiratory depression

    SpO2 (%)

    Time frame: through study completion, an average of 2 months

Secondary outcomes

  1. pain

    EVA

    Time frame: through study completion, an average of 2 months

  2. patient satisfaction

    satisfaction scale: 1=unsatisfied. 2=average satisfaction 3=Satisfied 4=very satisfied. The higher the value, the better. Additionally, we ask the patients if they would choose the same anesthetic method, should it be necessary to repeat the procedure. If yes, it is considered a better outcome.

    Time frame: through study completion, an average of 2 months

  3. pregnancy rate

    HCG in the blood

    Time frame: 15 days after the oocyte retrieval

  4. ketamine dosage

    blood sample (serum)

    Time frame: through study completion, an average of 2 months

  5. sedation level

    OAAS: Observer's Assessment Of Alertness/Sedation Scale. 5=Responds readily to name spoken in normal tone. 4=Lethargic response to name spoken in normal tone. 3=Response only after name is called loudly and/or repeatedly. 2=Response only after mild prodding or shaking. 1=Response only after paintful trapezius squeeze. 0=No response after paintful trapezius squeeze. Values higher than 3 represents a better outcome.

    Time frame: through study completion, an average of 2 months

  6. Arterial pressure

    mmHg

    Time frame: through study completion, an average of 2 months

  7. Heart rate

    Beats per minute

    Time frame: through study completion, an average of 2 months

  8. Pain

    NOL-index

    Time frame: through study completion, an average of 2 months

  9. Pain

    ANI

    Time frame: through study completion, an average of 2 months

  10. Sedation level

    Ramsay sedation scale. 1=Anxious and agitated or restless, or both. 2=Co-operative, oriented, and calm. 3=Responsive to commands only. 4=Exhibiting brisk response to light glabellar tap or loud auditory stimulus. 5=Exhibiting a sluggish response to light glabellar tap or loud auditory stimulus. 6=unresponsive. Values of 2-3 represent the better outcome.

    Time frame: through study completion, an average of 2 months

06

Study locations

1 of 1 sites recruiting
07

Registry details

Key details

Study ID
NCT03458143
Lead sponsor
Erasme University Hospital
Responsible party
Luc Barvais (MD PhD, Erasme University Hospital) — Principal investigator
First posted
Mar 8, 2018
Start date
Feb 12, 2018
Primary completion
Mar 31, 2018 (estimated)
Completion
Mar 31, 2018 (estimated)
Last update
Mar 13, 2018

Study contacts

barvais luc, MD PhD
Contact
luc.barvais@erasme.ulb.ac.be
+3225553919
Peres-Bota Iulia, student
principal investigator · Erasme hospital
Barvais Luc, MDPhD
study director · Erasme hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion